VISTAKON® Pharmaceuticals, LLC    Santen® Pharmaceutical, Co., LTD. T.R.U.S.T. QUIXIN® to keep you covered.

PROFESSIONALS

Comfortable Administration with Little or No Stinging

  • 97%-99% of patients did not report discomfort
  • Near-neutral pH (6.5)
  • No corneal precipitates

Levofloxacin: Minimal Cytotoxicity1


  • Human corneal endothelial cell and corneal keratocyte cytotoxicty were evaluated in vitro for 5 fluoroquinolones
  • Cells were cultured in solutions of each fluoroquinolone at varying concentration (10 ng/mL, 100 ng/mL, 1 μg/mL, 10 μg/mL, 100 μg/mL, and 1 mg/mL)
  • Cytotoxicity was measured at multiple exposure times

Cytotoxicity of Fluoroquinolones (1 µg/mL) Across Exposure Time

  • Results indicated that levofloxacin was less cytotoxic to both human corneal endothelial cells and keratocytes.
  • Clinical relevance of in vitro cytotoxicity has not been established

1%-3% of patients experienced any of the most frequent adverse events: transient decreased vision, fever, foreign body sensation, headache, transient ocular burning, ocular pain or discomfort, pharyngitis, and photophobia.


 

 

 

Events reported in less than 1% of patients include allergic reactions, lid edema, ocular dryness, and ocular itching. QUIXIN® is contraindicated in patients with a history of hypersensitivity to levofloxacin, to other quinolones, or to any of the components of this medication.


1. Skelnik DL, Clark LA, Bezwada P. In vitro effect of drug concentration and exposure time of levofloxacin, ofloxacin, ciprofloxacin, gatifloxacin, and moxifloxacin on human corneal endothelial cells and keratocytes. Presented at: ARVO Annual Meeting; May 4-9, 2003. Ft. Lauderdale, Fla. Poster #4739.